- About this Journal
- Abstracting and Indexing
- Aims and Scope
- Article Processing Charges
- Articles in Press
- Author Guidelines
- Bibliographic Information
- Citations to this Journal
- Contact Information
- Editorial Board
- Editorial Workflow
- Free eTOC Alerts
- Publication Ethics
- Reviewers Acknowledgment
- Submit a Manuscript
- Subscription Information
- Table of Contents
International Journal of Endocrinology
Volume 2012 (2012), Article ID 810926, 6 pages
Adjunctive Sitagliptin Therapy in Postoperative Cardiac Surgery Patients: A Pilot Study
1Winchester Medical Center, Heart and Vascular Center, Winchester, VA 22601, USA
2Department of Pharmacy Practice, Bernard J. Dunn School of Pharmacy, Shenandoah University, 1775 North Sector Court, Winchester, VA 22601, USA
Received 28 March 2012; Revised 16 August 2012; Accepted 30 August 2012
Academic Editor: Dariush Elahi
Copyright © 2012 Marcia L. Brackbill et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- Y. J. Chyan and L. M. Chuang, “Dipeptidyl peptidase-IV inhibitors: an evolving treatment for type 2 diabetes from the incretin concept,” Recent Patents on Endocrine, Metabolic & Immune Drug Discovery, vol. 1, no. 1, pp. 15–24, 2007.
- R. Mentlein, “Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides,” Regulatory Peptides, vol. 85, no. 1, pp. 9–24, 1999.
- C. F. Deacon, A. H. Johnsen, and J. J. Holst, “Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo,” Journal of Clinical Endocrinology and Metabolism, vol. 80, no. 3, pp. 952–957, 1995.
- Januvia (sitagliptin phosphate) Package Insert, Merck, Whitehouse Station, NJ, USA, 2007.
- R. E. Amori, J. Lau, and A. G. Pittas, “Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis,” Journal of the American Medical Association, vol. 298, no. 2, pp. 194–206, 2007.
- M. A. Nauck, G. Meininger, D. Sheng, et al., “Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial,” Diabetes, Obesity and Metabolism, vol. 9, no. 2, pp. 194–205, 2007.
- G. G. Sokos, H. Bolukoglu, J. German et al., “Effect of glucagon-like peptide-1 (GLP-1) on glycemic control and left ventricular function in patients undergoing coronary artery bypass grafting,” American Journal of Cardiology, vol. 100, no. 5, pp. 824–829, 2007.
- J. Larsen, B. Hylleberg, K. Ng, and P. Damsbo, “Glucagon-like peptide-1 infusion must be maintained for 24 h/day to obtain acceptable glycemia in type 2 diabetic patients who are poorly controlled on sulphonylurea treatment,” Diabetes Care, vol. 24, no. 8, pp. 1416–1421, 2001.
- J. Houser, “How many are enough? Statistical power analysis and sample size estimation in clinical research,” Journal of Clinical Research Best Practices, vol. 3, no. 3, 2007.
- S. Clement, S. S. Braithwaite, M. F. Magee et al., “Management of diabetes and hyperglycemia in hospitals,” Diabetes Care, vol. 27, no. 2, pp. 553–591, 2004.
- M. Guvener, I. Pasaoglu, M. Demircin, and M. Oc, “Perioperative hyperglycemia is a strong correlate of postoperative infection in type II diabetic patients after coronary artery bypass grafting,” Endocrine Journal, vol. 49, no. 5, pp. 531–537, 2002.
- S. E. Inzucchi, “Management of hyperglycemia in the hospital setting,” New England Journal of Medicine, vol. 355, no. 18, pp. 1903–1911, 2006.
- H. L. Lazar, S. R. Chipkin, C. A. Fitzgerald, Y. Bao, H. Cabral, and C. S. Apstein, “Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events,” Circulation, vol. 109, no. 12, pp. 1497–1502, 2004.
- T. Kotulák, J. Drápalová, P. Kopecký et al., “Increased circulating and epicardial adipose tissue mrna expression of fibroblast growth factor-21 after cardiac surgery: possible role in postoperative inflammatory response and insulin resistance,” Physiological Research, vol. 60, no. 5, pp. 757–767, 2011.